{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "country": "United States",
      "city": "Baltimore",
      "address_1": "111 S Calvert St Fl 21ST",
      "reason_for_recall": "CGMP Deviation; manufacturing batch record could not be located",
      "address_2": "",
      "product_quantity": "7,215 bottles",
      "code_info": "lot # F602820, Expiry December 2019",
      "center_classification_date": "20190116",
      "distribution_pattern": "Product was distributed to 12 major distributors who may have further distributed the product throughout the United States.",
      "state": "MD",
      "product_description": "Cephalexin for Oral Suspension USP, 250mg/5mL, 200 mL (when mixed), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India ---- NDC 68180-0124-02",
      "report_date": "20190123",
      "classification": "Class II",
      "openfda": {},
      "recalling_firm": "Lupin Pharmaceuticals Inc.",
      "recall_number": "D-0380-2019",
      "initial_firm_notification": "Letter",
      "product_type": "Drugs",
      "event_id": "81898",
      "termination_date": "20200708",
      "more_code_info": "",
      "recall_initiation_date": "20190107",
      "postal_code": "21202-6174",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "status": "Terminated"
    }
  ]
}